With rising COVID-19 cases, secondary schools will officially remain shut until 18 January - but primary schools across the country have also decided to stay closed.
As of midnight tonight (20 December), London and the South East will enter strict Tier 4 restrictions - which includes no household mixing over Christmas, and no commuting to work.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
The independent experts of the FDA say the Pfizer vaccine is good to go, which means that the COVID vaccine should be formally approved in a matter of days.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Pfizer/BioNTech COVID-19 vaccine for use in the UK and will be made available as early as next week.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
Rachel Thrasher, Research Fellow at the Global Development Policy Center in Boston, says this time is different and the TRIPS Council knows it - the COVID-19 vaccine needs to be freely accessible to all countries.
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
Asymptomatic older patients of COVID-19 are one of the most difficult to identify - now, researchers find that delirium could be an indicator of the virus
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
Gino Martini, RPS Chief Scientist and the Science and Research Team at the Royal Pharmaceutical Society reflect on the role of pharmacy during COVID-19 in delivering accessible, safe and effective care for all.
European Public Health Association Executive Director, Dineke Zeegers Paget examines COVID-19 as a societal issue, not just a pandemic and argues that solidarity here is needed the most.
